Novartis gets EC approval for Enerzair Breezhaler plus digital companion
The approval indicated the drug for uncontrolled asthma in patients who experienced one or more asthma exacerbations in…
Novavax secures $1.6bn funding for Covid-19 vaccine development
08 Jul 20The funding will support the late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure and…
FDA approves Abbott’s Gallant family of defibrillator devices
07 Jul 20Abbott’s Gallant implantable cardioverter defibrillator family of devices are capable of connecting patients and doctors via Bluetooth
CureVac to receive $85m EIB financing for Covid-19 vaccine programme
07 Jul 20CureVac has reached a loan agreement with EIB for the development and production of vaccine candidate against SARS-CoV-2
ViiV Healthcare unveils positive data from CUSTOMIZE trial
06 Jul 20Cabotegravir plus rilpivirine is an investigational regimen indicted for the treatment of HIV-1 infection in patients who are…
Gilead gets EC conditional marketing authorisation for Veklury to treat Covid-19
06 Jul 20The conditional marketing authorisation was granted based on the US National Institute of Allergy and Infectious Diseases’ global…
ViiV Healthcare gets FDA approval for Rukobia to treat HIV in adults
03 Jul 20In the Phase 3 BRIGHTE trial, 60% of heavily treatment-experienced adults receiving Rukobia with an optimised background therapy…
EC expands Invokana indication to include CREDENCE trial data
03 Jul 20The EC approval is based on the Phase 3 CREDENCE trial, which was stopped early after a planned…
Novartis to pay $678m to resolve legacy litigation with US authorities
02 Jul 20Novartis has reached a settlement with the US Attorney’s Office for the Southern District of New York, the…
Janssen secures EC approval for preventive Ebola vaccine
02 Jul 20The Ebola vaccine regimen has been developed by leveraging Janssen’s AdVac technology, and Bavarian Nordic’s MVA-BN technology